Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$4.9 million.

  • Lyell Immunopharma's Non Operating Income fell 18205.0% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year increase of 650.57%. This contributed to the annual value of $15.8 million for FY2024, which is 2735.13% up from last year.
  • As of Q3 2025, Lyell Immunopharma's Non Operating Income stood at -$4.9 million, which was down 18205.0% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Non Operating Income ranged from a high of $9.2 million in Q4 2024 and a low of -$36.2 million during Q4 2021
  • For the 5-year period, Lyell Immunopharma's Non Operating Income averaged around $73842.1, with its median value being $938000.0 (2022).
  • As far as peak fluctuations go, Lyell Immunopharma's Non Operating Income surged by 92142.86% in 2021, and later crashed by 143461.54% in 2022.
  • Over the past 5 years, Lyell Immunopharma's Non Operating Income (Quarter) stood at -$36.2 million in 2021, then skyrocketed by 117.66% to $6.4 million in 2022, then increased by 2.99% to $6.6 million in 2023, then skyrocketed by 40.04% to $9.2 million in 2024, then plummeted by 152.75% to -$4.9 million in 2025.
  • Its Non Operating Income stands at -$4.9 million for Q3 2025, versus $4.5 million for Q2 2025 and $5.2 million for Q1 2025.